Etoposide-related acute promyelocytic leukemia

Leukemia

Volumn 12, Issue 8, 1998, Pages 1171-1175

  Kudo, K ^a   Yoshida, H ^b   Kiyoi, H ^b   Numata, S ^a   Horibe, K ^a   Naoe, T ^b  

^a NAGOYA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b NAGOYA UNIVERSITY HOSPITAL   (Japan)

Author keywords

Acute promyelocytic leukemia; Etoposide; Langerhans cell histiocytosis; PML RAR ; Therapy related leukemia

Indexed keywords

ALKYLATING AGENT; ETOPOSIDE;

ACUTE MYELOBLASTIC LEUKEMIA; ADULT; AGED; ARTICLE; CHILD; CHROMATIN STRUCTURE; CHROMOSOME TRANSLOCATION; CLINICAL ARTICLE; FEMALE; HISTIOCYTOSIS; HUMAN; INFANT; LANGERHANS CELL; MALE; PRIORITY JOURNAL;

EID: 0031877960     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.leu.2401089     Document Type: Article

References (13)

1. Whitlock JA, Greer JP, Lukens JN. Epipodophyllotoxin-related leukemia. Identification of a new subset of secondary leukemia. Cancer 1991; 68: 600-604.
2. Winick NJ, McKenna RW, Shuster JJ, Schneider NR, Borowitz MJ, Bowman WP, Jacaruso D, Kamen BA, Buchanan GR. Secondary acute myeloid leukemia in children with acute lymphoblastic leukemia treated with etoposide. J Clin Oncol 1993; 11: 209-217.
3. Pedersen-Bjergaard J, Daugaard G, Hansen SW, Philip P, Larsen SO, Rorth M. Increased risk of myelodysplasia and leukaemia after etoposide, cisplatin, and bleomycin for germ-cell tumours. Lancet 1991; 338: 359-363.
4. Pedersen-Bjergaard J, Philip P, Larsen SO, Jensen G, Byrsting K. Chromosome aberrations and prognostic factors in therapy-related myelodysplasia and acute nonlymphocytic leukemia. Blood 1990; 76: 1083-1091.
5. Pedersen-Bjergaard J, Philip P, Larsen SO, Andersson M, Daugaard G, Ersboll J, Hanses SW, Hou-Jenses K, Nielsen D, Sigsgaard TC, Specht L, Osterlind K. Therapy-related myelodysplasia and acute myeloid leukemia. Cytogenetic characteristics of 115 consecutive cases and risk in seven cohorts of patients treated intensively for malignant diseases in the Copenhagen series. Leukemia 1993; 7: 1975-1986.
6. Pedersen-Bjergaard J, Rowley JD. The balanced and the unbalanced chromosome aberrations of acute myeloid leukemia may develop in different ways and may contribute differently to malignant transformation. Blood 1994; 83: 2780-2786.
7. Pedersen-Bjergaard J, Pedersen M, Roulston D, Philip P. Different genetic pathways in leukemogenesis for patients presenting with therapy-related myelodysplasia and therapy-related acute myeloid leukemia. Blood 1995; 86: 3542-3552.
8. Quesnel B, Kantarjian H, Pedersen-Bjergaard J, Brault P, Estey E, Lai JL, Tilly H, Stoppa AM, Archimbaud E, Harousseau JL, Bauters F, Fenaux P. Therapy-related acute myeloid leukemia with t(8;21), inv(16), and t(8;16): a report on 25 cases and review of the literature. J Clin Oncol 1993; 11: 2370-2379.
9. Pedersen-Bjergaard J, Brondum-Nielsen K, Karle H, Johansson B. Chemotherapy-related and late-occurring Philadelphia chromosome in AML, ALL and CML. Similar events related to treatment with DNA topoisomerase II inhibitors? Leukemia 1997; 11: 1571-1574.
10. Smith MA, Rubinstein L, Ungerleider RS. Therapy-related acute myeloid leukemia following treatment with epipodophyllotoxins: estimating the risks. Med Pediat Oncol 1994; 23: 86-98.
11. Berger N, Chatterjee S, Schmotzer J, Helms S. Etoposide (VP-16-213)-induced gene alterations: potential contribution to cell death. Proc Natl Acad Sci USA 1991 ; 88: 8740-8743.
12. Spitzner JR, Muller MT. A consensus sequence for cleavage by vertebrate DNA topoisomerase II. Nucleic Acids Res 1988; 16: 5533-5554.
13. Spitzner JR, Chung IK, Gootz TD, McGuirk PR, Muller MT. Analysis of eukaryotic topoisomerase II cleavage sites in the presence of the quinolone CP-115,953 reveals drug-dependent and -independent recognition elements. Molec Pharmacol 1995; 48: 238-249.